Mankind Pharma Faces Rs 341.86 Cr Tax Demand

New Delhi: Mankind Pharma Ltd on Wednesday said it has received additional tax demands, including interest, of Rs 341.86 crore from the Income Tax authority.

The company has received orders from the office of the Deputy Commissioner of Income Tax, Central Circle 29, New Delhi dated May 9, 2025 on May 13 and 14, 2025, through IT portal, raising additional tax demands, including interest, of Rs 341.86 crore, Mankind Pharma said in a regulatory filing.

The demand is on account of adjustments made and disallowance of various expenditures under different sections of the Income Tax Act, 1961, it added.

The company said it believes that “the demands under the orders are not tenable in law”, asserting it has adequate factual and legal grounds to substantiate its position and does not expect any material impact on financials or its operations due to the orders.

Mankind Pharma said it would pursue an appeal against the said orders under applicable laws.

Related Posts

Udan vs Udaan: Delhi court restrains pharmaceutical firm from using ‘Udaan’ mark

New Delhi: A Delhi court has permanently restrained a Hyderabad-based pharmaceutical company from using the trademark ‘Udaan’ or any similar mark, ruling that it was a clear violation of the…

Three newborns die in fire at government hospital in Amravati, Maharashtra

Maharashtra Revenue Minister Chandrashekhar Bawankule said that a complete inquiry into the incident is underway and the injured are being treated. Three newborn babies died after a fire broke out…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Udan vs Udaan: Delhi court restrains pharmaceutical firm from using ‘Udaan’ mark

Udan vs Udaan: Delhi court restrains pharmaceutical firm from using ‘Udaan’ mark

Three newborns die in fire at government hospital in Amravati, Maharashtra

Three newborns die in fire at government hospital in Amravati, Maharashtra

Maharashtra FDA to prioritise process audits for revised Schedule M compliance: FDA Commissioner

Maharashtra FDA to prioritise process audits for revised Schedule M compliance: FDA Commissioner

Centre bans fixed-dose combination for Common Cold in children below four

Centre bans fixed-dose combination for Common Cold in children below four

New research study proposes a unifying theory for Alzheimer’s disease and other neurodegenerative diseases

New research study proposes a unifying theory for Alzheimer’s disease and other neurodegenerative diseases

Brain organoid maturation is driven by a lifelike developmental clock: Study

Brain organoid maturation is driven by a lifelike developmental clock: Study